Literature DB >> 10545485

Development of an assay to measure in vivo cytokine production in the mouse.

F D Finkelman1, S C Morris.   

Abstract

The short in vivo lifespan of many cytokines can make measurement of in vivo cytokine production difficult. A method was developed to measure in vivo IL-4 and IFN-gamma production that eliminates this problem. Mice are injected with a biotin-labeled neutralizing IgG anti-IL-4 or anti-IFN-gamma mAb and bled 2-24 h later. Secreted cytokine is captured by the biotin-labeled mAb to produce a complex that has a relatively long in vivo half-life and consequently accumulates in serum. Serum concentrations of the complex are determined by ELISA, using wells coated with an antibody to a second epitope on the same cytokine to capture the complex. This technique is specific and increases sensitivity of detection of secreted IL-4 at least 1000-fold. The amount of cytokine measured is directly proportional to the amount produced and relatively independent of the site of cytokine production. Furthermore, because mice are injected with small quantities of biotin-labeled anti-cytokine mAb, which sample, rather than neutralize, all secreted cytokines, cytokine-dependent responses are not inhibited. The in vivo half-lives of the cytokine-anti-cytokine mAb complexes are sufficiently short to allow cytokine production to be measured every 2-3 days in the same mice. Thus, use of this assay provides a practical and relatively simple and inexpensive way to measure ongoing in vivo cytokine production. Furthermore, the techniques that have been developed to measure in vivo production of IL-4 and IFN-gamma can be applied to in vivo measurement of other molecules that have a short in vivo lifespan, including other cytokines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545485     DOI: 10.1093/intimm/11.11.1811

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  49 in total

1.  Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen.

Authors:  Kris A Steinbrecher; Netanel A Horowitz; Elizabeth A Blevins; Kelley A Barney; Maureen A Shaw; Eleana Harmel-Laws; Fred D Finkelman; Matthew J Flick; Malinda D Pinkerton; Kathryn E Talmage; Keith W Kombrinck; David P Witte; Joseph S Palumbo
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

2.  Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.

Authors:  M Zhang; K Howard; A Winters; S Steavenson; S Anderson; S Smelt; G Doellgast; C Sheelo; J Stevens; H Kim; A Hamburger; A Sein; D J Caughey; F Lee; H Hsu; G Siu; F R Byrne
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

3.  Reconfigurable microfluidic device with integrated antibody arrays for capture, multiplexed stimulation, and cytokine profiling of human monocytes.

Authors:  Tam Vu; Ali Rahimian; Gulnaz Stybayeva; Yandong Gao; Timothy Kwa; Judy Van de Water; Alexander Revzin
Journal:  Biomicrofluidics       Date:  2015-08-06       Impact factor: 2.800

4.  IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking.

Authors:  Richard T Strait; Suzanne C Morris; Fred D Finkelman
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

5.  Differential regulation of IL-4Ralpha expression by antigen versus cytokine stimulation characterizes Th2 progression in vivo.

Authors:  Georgia Perona-Wright; Katja Mohrs; Katrin D Mayer; Markus Mohrs
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

6.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  TGF-β-responsive myeloid cells suppress type 2 immunity and emphysematous pathology after hookworm infection.

Authors:  Lisa Heitmann; Reena Rani; Lucas Dawson; Charles Perkins; Yanfen Yang; Jordan Downey; Christoph Hölscher; De'Broski R Herbert
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

8.  Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells.

Authors:  Mark S Wilson; John T Pesce; Thirumalai R Ramalingam; Robert W Thompson; Allen Cheever; Thomas A Wynn
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection.

Authors:  De'Broski R Herbert; Jun-Qi Yang; Simon P Hogan; Kathryn Groschwitz; Marat Khodoun; Ariel Munitz; Tatyana Orekov; Charles Perkins; Quan Wang; Frank Brombacher; Joseph F Urban; Marc E Rothenberg; Fred D Finkelman
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

10.  Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.

Authors:  YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.